The use of virtual reality (VR) in the oncology space has gained increased attention in the past years, with its use ranging from reducing anxiety in patients through virtual environments to educating and training medical professionals. New research by Ram A. Pathak, MD, and colleagues has analyzed the utility of a VR model developed with patient-derived clinical imaging to improve patient understanding of diagnosis and surgical plans in those with localized prostate cancer (PCa). ...
Localized Prostate Cancer
Advertisement
Latest News
Data show that of patients with prostate cancer, Black men face higher incidence and mortality rates than White men.
For the treatment of localized prostate cancer, guidelines typically recommend the addition of ADT to RT in certain patients.
Drs. Stifelman and Ambinder discuss the novel approaches and adoption challenges of single-port and Da Vinci 5 systems.
Dr. Shore discusses treatment-related adverse events associated with apalutamide and ADT.
Dr. Shore discusses the effects of apalutamide plus ADT in patients with prostate cancer.
Drs. Joshua and Wallis contextualize the Metformin Active Surveillance Trial for management of low-risk prostate cancer.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content based on prostate cancer types, therapies, and technologies
Conference Coverage
The first part of five segments from the live podcast, roundtable session on radioligands.
During the final part of this panel, novel ADCs are explored and analyzed for use in different settings.
During the fourth segment of this panel, novel ADCs including HER3, Nectin-4, and BT8009 are analyzed.
In the third part of this panel, the use of HER2 ADCs in bladder cancer is explored.
In the second segment of this panel, the use of sacituzumab govitecan monotherapy and combinations is discussed.
In the first part of this panel, the use and impact of enfortumab vedotin in the bladder cancer landscape is considered.
Advertisement
Advertisement
Trending
The first part of five segments from the live podcast, roundtable session on radioligands.
Part three of this prostate cancer roundtable covers prognostic factors such as Gleason scores and genomic assays.
Part two of this roundtable features a discussion on the role of bone scans compared to the newer PSMA PET scans.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.